Home
overview

"The Doctor does not treat mankind except accidentally...So if someone...
knows the universal without knowing the individuals contained in it, he will often fail in his
treatment; for it is the individual that has to be treated."


Aristotle, Metaphysics

What is this event about?

About the conference

Following the successes of our previous events on pharmacogenomics, biomarkers and stem cells, SMi is proud to present its inaugural conference on Personalised Medicine.

Taking place in London, UK, this conference will look at the latest in science, R&D, business strategies and legal issues for developing personalised therapeutics, and successfully introducing them to the marketplace.

Covering various approaches towards developing personalised therapeutics - biomarkers, pharmacogenomics, pharmacogenetics and stem cells, the conference will introduce both a pharmaceutical industry and a diagnostics industry perspective on the best way to move forward with developing companion diagnostics, marketing strategies, reimbursement issues and making personalised medicine viable in a commercial marketplace.

Issues considered during the conference will include:

  • Should pharma develop companion diagnostics internally, partner, or acquire diagnostic technologies?
  • Is co-development the best method for companion diagnostics?
  • What is the regulatory perspective on stratified and personalised therapeutics?
  • How can the industry be creative with partnering strategies?
  • Can current blockbuster drugs be repositioned as personalised medicines through resequencing?
  • How do we identify and validate biomarkers for personalised medicines?
  • Are pharmacogenomics and pharmacogenetics the right way forward?
  • How far can stem cell technologies be used to personalise therapeutics?

Why not attend the associated workshop as well?

Associated with the conference there will be a half-day interactive workshop on "What's Holding Personalised Medicine Back - How Can We Move It Forward?", taking place on 13th October.  It will cover biomarker validation and qualification, clinical trial design and analysis for personalised therapeutics and intellectual property, ethical and policy issues.  This will be led by Shawnmarie Mayrand-Chung from the Biomarkers Consortium at the US National Institutes of Health.  To see more information about the workshop, please see the Personalised Medicine workshop page.

Keen to see the detailed programme?  Click here.

Want to download the brochure?  Click here.

Register for the event here!

Group discounts available - click here

 

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know: contact the Conference Producer.

For sponsorship and exhibitioning opportunities, contact our Sponsorship Department.

 

Why should you attend this event?

What you will learn about

  • The state of the market: the pharma and diagnostics perspective on how to develop and market personalised medicines and their companion diagnostics
  • Research and development: the latest developments in R&D
  • Pharmacogenomics: using pharmacogenomics and pharmacogenetics to develop personalised therapeutics
  • Biomarkers: Identifying, developing and validating biomarkers as tools for personalised medicine
  • Stem cells: Using stem cell technology to implement a more personalised therapeutic regime
 Discovering the pharmacogenomic approach
 Studying the pharmacogenetic approach

How you will benefit

Hear from some of the leading experts in the science and business development of personalised medicines

Learn the differing views and strategies of pharma and diagnostics

Discover the best ways to manage partnerships and develop companion diagnostics

Network with the experts you need to know in the personalised medicine arena

Who should attend this event?

Chief Executives, Vice Presidents, Heads, Directors, Chief Scientists and Project Leaders of

  • Personalised Medicine / Therapeutics
  • Pharmacogenomics
  • Pharmacogenetics
  • Molecular Diagnostics
  • Companion Diagnostic Development
  • Strategic Partnering
  • Business Development
  • Worldwide Commercial Development
  • Translational Sciences/Medicine
  • Experimental Medicine
  • Biomarkers
  • Marketing

Delegates at our previous biomarkers and stem cells conferences came from across the world

Former delegates at events similar to personalised medicine

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Cecilia Schott

Cecilia Schott, Director of Business Development, AstraZeneca

9:10 Strengthening big pharma's personalised medicine pipeline via partnerships with diagnostics companies

Cecilia Schott

Cecilia Schott, Director of Business Development, AstraZeneca

  • Developing a forward-looking pipeline
  • In-house or partnerships?
  • Examples from AstraZeneca experience
  • 9:50 Pfizer/Abbott Molecular collaboration:

    Hakan Sakul

    Hakan Sakul, Senior Director, Translational Oncology Group, Pfizer

  • Our increased understanding of molecular pathways in oncology in recent years has contributed to the development of diagnostics assays that enable implementation of personalised medicine
  • Most pharma companies rely on collaborations with diagnostics companies for the development and commercialisation of companion diagnostics assays
  • Pharma and Dx companies traditionally have different paths to markets, each party has to rely on the success of the other to successfully co-develop Rx and Dx
  • This presentation will focus on a case study for a late-stage NSCLC compound and will outline the development of a companion diagnostic assay being used in patient identification
  • 10:15 Pfizer/Abbott Molecular collaboration:

    Niko Drivas

    Niko Drivas, Senior Licensing Manager, Abbott Molecular

  • The contract 
  • Facilitating the regulatory strategy 
  • Critical elements of clinical studies 
  • Delivering commercial value 
  • Alliance management: maximizing the partnership dynamics
  • 10:40 Pfizer/Abbott Molecular collaboration: Q&A

    Hakan Sakul

    Hakan Sakul, Senior Director, Translational Oncology Group, Pfizer

    Niko Drivas

    Niko Drivas, Senior Licensing Manager, Abbott Molecular

    10:50 Morning coffee

    11:20 Creative models for companion diagnostic development

    Carol Berry

    Carol Berry, Vice President and General Manager Pharmacogenomic and CLIA Services, Asuragen

  • What development models will the FDA accept?
  • Building in flexibility
  • Creative marketing models
  • 12:00 Partnering for companion test development: perspective of a global IVD company

    Iain Miller

    Iain Miller, Executive Director, Theranostics Strategy and Business Development, bioMérieux

  • Drivers and challenges associated with partnering
  • Case study examples of specific deals
  • Broad strategy
  • 12:40 Networking lunch

    13:40 PANEL DISCUSSION

  • Differing models
  • Accelerating development
  • Business factors
  • Iain Miller

    Iain Miller, Executive Director, Theranostics Strategy and Business Development, bioMérieux

    Patrik Kolar

    Patrik Kolar, Head of Unit, Directorate-General for Research Genomics and Systems Biology, European Commission

    Eddie Blair

    Eddie Blair, Director, Integrated Medicines

    14:20 Deep resequencing as a tool for drug repositioning

    John Whittaker

    John Whittaker, Director, Statistical Genetics, GlaxoSmithKline

  • Deep resequencing provides a powerful tool for drug development via the exhaustive discovery of genetic variation in drug targets
  • Novel associations of such variants with disease can suggest new uses for existing drugs
  • Here we discuss an ongoing experiment on 200 genes and 15,000 individuals
  • 15:00 Afternoon tea

    15:30 The rough guide to outsourcing of genomics activities

    Ian White

    Ian White, Associate Director, Experimental Medicine, UCB Celltech

  • Selecting the destination
  • Planning the route
  • Making the most of what you find when you get there
  • 16:10 Valuing companion diagnostics

    Eddie Blair

    Eddie Blair, Director, Integrated Medicines

  • Development of companion diagnostics and personalised medicine
  • Assessment of the true value of companion diagnostics
  • Impact of valuation on relationships, regulation and reimbursement
  • 16:50 Application of stem cells in pharmacological and toxicological screening

    Balazs Sarkadi

    Balazs Sarkadi, Head, Membrane Biology Research Group, Hungarian Academy of Sciences

  • Using HuESCs and iPSCs as relevant model systems in toxicology and pharmacology screening
  • Genetically engineering human pluripotent stem cells to express reporter constructs
  • Differentiating reporter cell lines into specific tissue types
  • Screening for modulation of differentiation and sensitivity of cell types
  • Role in new drug development, assessing environmental toxicity and reducing animal experiments
  • 17:30 Chairman’s closing remarks and close of day one

    8:30 Re-registration and coffee

    9:00 Chairman's opening remarks

    Martin Wilkins

    Martin Wilkins, Professor of Clinical Pharmacology and Head of the Division of Experimental Medicine, Imperial College London

    9:10 European-"omics" Collaborative's research - facilitating the progress of personalised medicine

    Patrik Kolar

    Patrik Kolar, Head of Unit, Directorate-General for Research Genomics and Systems Biology, European Commission

  • Philosophy of the Collaborative's research in the EU Framework Research Programmes and their application in Health Research
  • Structure of the Health Programme and the position of the "omics"-related activities in it
  • Success stories in "omics" research funded so far enabling personalised medicine
  • Forward look
  • 9:50 The development of multigene prognostic and predictive tests for cancer management

    Austin Tanney

    Austin Tanney, Scientific Liaison Manager, Almac Group

  • Oncology is a primary focus for personalised medicine
  • Cancer treatment needs to be better tailored to improve patient outcome
  • Discussion of issues involved in the development of prognostic and predictive tests
  • 10:30 Morning coffee

    11:00 Stratified approaches to the management of common respiratory diseases

    Ian Hall

    Ian Hall, Dean, Faculty of Medicine and Health Sciences, University Of Nottingham

  • The potential to use stratified approaches to define patient populations with different treatment requirements or different treatment responses in respiratory disease
  • Focus on asthma and COPD
  • The use of genetics and other approaches to stratify patients
  • Regulatory issues
  • 11:40 Biomarkers in drug development: some statistical issues - with a focus on cardiovascular diseases

    Ziad Taib

    Ziad Taib, Statistical Science Director, AstraZeneca

  • Biomarkers in drug development
  • Types of biomarkers
  • Analytical evaluation and validation of biomarkers
  • Statistical issues
  • A few CV examples
  • 12:20 Networking lunch

    13:50 Patient adherence: implications for personalised medicine

    Rob Horne

    Rob Horne, Director, Centre for Behavioural Medicine, School of Pharmacy, University of London

  • The capacity of personalised medicine to improve health outcomes is dependent on patient adherence
  • Over a third of prescribed medicines are not taken as advised
  • This session will examine the reasons for nonadherence to medicines and explore the implications for personalised medicine
  • 14:30 Reducing cardiovascular risk: diagnosis and treatment of endothelial dysfunction

    Roger Corder

    Roger Corder, Professor of Experimental Therapeutics, William Harvey Research Institute, Queen Mary University of London

  • Characteristics of endothelial dysfunction and influence on cardiovascular risk 
  • Patient groups requiring assessment of endothelial function 
  • Need for biomarkers of endothelial dysfunction
  • Treatment options for endothelial dysfunction
  • 15:10 Afternoon tea

    15:40 Current challenges to the regulatory framework

    Lincoln Tsang

    Lincoln Tsang, Partner, Arnold and Porter LLP

  • Will the regulatory threshold for product approval be changed?
  • How this will impact the benefit/risk assessment paradigm
  • Will this likely expedite patient access to innovative medicines?
  • 16:20 A stratified medicines initiative for the UK

    Angela Flannery

    Angela Flannery, Lead Specialist, Stratified Medicines, Technology Strategy Board

  • Announcement about the Technology Strategy Board's competition for genomics research projects in the UK
  • 17:00 Chairman’s closing remarks and close of day two

    +

    Crowne Plaza - The City

    19 New Bridge Road
    London EC4V 6DB
    United Kingdom

    Crowne Plaza - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.